Actualisation du référentiel régional Cancer du sein : découvrez-le sans plus tarder
-
Titre abrégé
Libelule
-
NCT
-
Phase de l'essai
- Phase III
-
Type de promoteur
Académique / Institutionnel
-
Nom du promoteur
CENTRE LEON BERARD
-
I1. Age e" 18 years, I2. Patients with clinico-radiological suspicious presentation of lung cancer locally advanced not amendable to a locoregional treatment or stage IV, I3. No prior chemotherapy for locally advanced or metastatic NSCLC, I4. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2, I5. Life expectancy > 12 weeks, I6. No contraindication to systemic lung cancer treatment, I7. No planned or previous inclusion in another 1st line therapy study, I8. Covered by a medical insurance, I9. Signed informed consent prior to any study-specific procedure, I10. No prior biopsy or cytology for this lung cancer diagnosis
-
Pregnant or breastfeeding woman, E2. Patient concurrently using other approved or investigational antineoplastic agents, E3. Major concurrent disease affecting cardiovascular system, liver, kidneys, hematopoietic system or else considered as clinically important by the investigator and that could be incompatible with patient s participation in this trial or would likely interfere with study procedures or results, E4. Prior history of malignancies other than study disease (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix) unless the patient has been free of the disease for at least 3 years, E5. Patient requiring tutorship or curatorship.
-
Nom du centre
HCL - Hôpital Louis Pradel
Lyon -
Contact Investigateur
-
Nom
Michael DURUISSEAUX
-
Contact ARC/TER/IRC
-
Nom
Raphaele GUELMINGER